Verrica Pharmaceuticals announced that the U.S. Food and Drug Administration FDA accepted for filing the Company’s resubmitted New Drug Application NDA for VP-102 for the treatment of molluscum contagiosum and assigned a Prescription Drug User Fee Act PDUFA goal date of July 23. "We are pleased that the FDA has accepted for filing our NDA resubmission for VP-102," said Ted White, Verrica’s President and Chief Executive Officer. "With no FDA-approved treatments for molluscum, the filing acceptance of our NDA brings us one step closer towards providing a safe and effective therapeutic treatment option for the millions of patients in the United States with molluscum. VP-102 has been designed for reliable and targeted administration of cantharidin through a unique, topical, GMP-controlled formulation through a single-use applicator. Based upon the strong safety and efficacy results from our two Phase 3 clinical trials, we believe that VP-102 has the potential to offer an important new treatment option for molluscum."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VRCA:
- Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
- Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
- Verrica Pharmaceuticals prices $32.5M offering of common stock/warrants at $6.75
- Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- RBC upgrades Verrica Pharmaceuticals to Outperform on improved VP-102 view
